WO2010122531A2 - Method - Google Patents
Method Download PDFInfo
- Publication number
- WO2010122531A2 WO2010122531A2 PCT/IB2010/051802 IB2010051802W WO2010122531A2 WO 2010122531 A2 WO2010122531 A2 WO 2010122531A2 IB 2010051802 W IB2010051802 W IB 2010051802W WO 2010122531 A2 WO2010122531 A2 WO 2010122531A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nucleotide sequence
- lipolytic enzyme
- enzyme
- sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 108090000790 Enzymes Proteins 0.000 claims abstract description 354
- 102000004190 Enzymes Human genes 0.000 claims abstract description 350
- 239000002773 nucleotide Substances 0.000 claims abstract description 286
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 286
- 230000002366 lipolytic effect Effects 0.000 claims abstract description 238
- 241000499912 Trichoderma reesei Species 0.000 claims abstract description 84
- 230000014509 gene expression Effects 0.000 claims abstract description 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 59
- 230000000295 complement effect Effects 0.000 claims abstract description 32
- 238000012258 culturing Methods 0.000 claims abstract description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 9
- 229940088598 enzyme Drugs 0.000 claims description 340
- 108090000623 proteins and genes Proteins 0.000 claims description 129
- 230000000694 effects Effects 0.000 claims description 58
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 34
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 27
- 230000009466 transformation Effects 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229910001868 water Inorganic materials 0.000 claims description 16
- 238000006206 glycosylation reaction Methods 0.000 claims description 13
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 claims description 12
- 230000001131 transforming effect Effects 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 11
- 230000013595 glycosylation Effects 0.000 claims description 11
- 239000012228 culture supernatant Substances 0.000 claims description 8
- 108010059892 Cellulase Proteins 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 109
- 239000002609 medium Substances 0.000 description 84
- 108020004414 DNA Proteins 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 66
- 101710084376 Lipase 3 Proteins 0.000 description 55
- 239000012634 fragment Substances 0.000 description 50
- 238000000855 fermentation Methods 0.000 description 43
- 230000004151 fermentation Effects 0.000 description 43
- 108090001060 Lipase Proteins 0.000 description 37
- 101150089778 pyr-4 gene Proteins 0.000 description 37
- 102000004882 Lipase Human genes 0.000 description 34
- 239000000758 substrate Substances 0.000 description 32
- 239000004367 Lipase Substances 0.000 description 31
- 235000019421 lipase Nutrition 0.000 description 31
- 238000003556 assay Methods 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 23
- 238000012217 deletion Methods 0.000 description 23
- 230000037430 deletion Effects 0.000 description 23
- 241000228232 Aspergillus tubingensis Species 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 101150114858 cbh2 gene Proteins 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 19
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 18
- 235000010633 broth Nutrition 0.000 description 17
- 235000019626 lipase activity Nutrition 0.000 description 16
- 244000005700 microbiome Species 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 241000233866 Fungi Species 0.000 description 11
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 235000013351 cheese Nutrition 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 10
- 238000004520 electroporation Methods 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- -1 egM Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 101000899859 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) Endoglucanase 1 Proteins 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 101710098247 Exoglucanase 1 Proteins 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 101150052795 cbh-1 gene Proteins 0.000 description 7
- 230000022811 deglycosylation Effects 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 241000228212 Aspergillus Species 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 6
- 102100027441 Nucleobindin-2 Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 210000001938 protoplast Anatomy 0.000 description 6
- 235000015067 sauces Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 6
- 229940045145 uridine Drugs 0.000 description 6
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 5
- 241000223259 Trichoderma Species 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 229910001882 dioxygen Inorganic materials 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 101150028074 2 gene Proteins 0.000 description 4
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 101710126559 Endoglucanase EG-II Proteins 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012970 cakes Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 101150066032 egl-1 gene Proteins 0.000 description 4
- 101150003727 egl2 gene Proteins 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 239000005417 food ingredient Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 239000010937 tungsten Substances 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101710098246 Exoglucanase 2 Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108010043958 Peptoids Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 101150069003 amdS gene Proteins 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000004213 low-fat Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000007003 mineral medium Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- JEGLJLCZRAWOBI-UHFFFAOYSA-N rac-1,2-di-O-dodecanylglycero-3-glutaric acid 6'-methylresorufin ester Chemical compound C1=CC(=O)C=C2OC3=C(C)C(OC(=O)CCCC(=O)OCC(COCCCCCCCCCCCC)OCCCCCCCCCCCC)=CC=C3N=C21 JEGLJLCZRAWOBI-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010084185 Cellulases Proteins 0.000 description 2
- 102000005575 Cellulases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 229940025131 amylases Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010018734 hexose oxidase Proteins 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000005257 nucleotidylation Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000012510 peptide mapping method Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- ZDRLKQLULCHOAJ-SECBINFHSA-N (2S)-2-amino-2,3,3-trifluoro-3-(4-hydroxyphenyl)propanoic acid Chemical compound FC([C@](N)(C(=O)O)F)(C1=CC=C(C=C1)O)F ZDRLKQLULCHOAJ-SECBINFHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- BWKMGYQJPOAASG-VIFPVBQESA-N (3s)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-VIFPVBQESA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- PDLPTSJWDUCMKS-UHFFFAOYSA-N 3-[4-(3-sulfopropyl)piperazin-1-yl]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN1CCN(CCCS(O)(=O)=O)CC1 PDLPTSJWDUCMKS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 101710156497 Endoglucanase H Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108020000949 Fungal DNA Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108050008938 Glucoamylases Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 1
- 229910014130 Na—P Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000574469 Penicillium allii Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 101001095983 Staphylococcus aureus Protein rep Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000223257 Thermomyces Species 0.000 description 1
- 241000223258 Thermomyces lanuginosus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- KYOBSHFOBAOFBF-UHFFFAOYSA-N UMP Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021168 barbecue Nutrition 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000020140 chocolate milk drink Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000015142 cultured sour cream Nutrition 0.000 description 1
- 108010005400 cutinase Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010091371 endoglucanase 1 Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000005254 filamentous fungi cell Anatomy 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 101150087371 gpd1 gene Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- KYOBSHFOBAOFBF-ZAKLUEHWSA-N orotidine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-ZAKLUEHWSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010087558 pectate lyase Proteins 0.000 description 1
- 108010072638 pectinacetylesterase Proteins 0.000 description 1
- 102000004251 pectinacetylesterase Human genes 0.000 description 1
- 108020004410 pectinesterase Proteins 0.000 description 1
- 230000002351 pectolytic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- VKFFEYLSKIYTSJ-UHFFFAOYSA-N tetraazanium;phosphonato phosphate Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[O-]P([O-])(=O)OP([O-])([O-])=O VKFFEYLSKIYTSJ-UHFFFAOYSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 235000012184 tortilla Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Definitions
- WO 98/45453 discloses a lipolytic enzyme (and variants thereof) derived from the filamentous fungus Aspergillus tubingensis. This enzyme is sometimes referred to as "lipase 3" WO 98/45453 characterizes several of the physicochemical characteristics of lipase 3. Uses of this lipolytic enzyme for improving the properties of bread were also described, in particular for improving the properties of bread
- WO 98/45453 also described the cloning and expression of lipase 3 and its variants in Aspergillus tubing ⁇ nsis. It was found that this lipolytic enzyme could be overexpressed in Aspergillus tubingensis, however the enzyme was overglycosylated in A tubingensis which, in some situations, can decrease its activity.
- a method of producing a lipolytic enzyme comprising the steps of,
- nucleotide sequence comprises the nucleotide sequence shown as SEQ ID NO. 3 or SEQ ID NO: 4 or a nucleotide sequence which has at least 40% sequence identity to SEQ ID NO: 3 or SEQ ID NO. 4, and/or
- nucleotide sequence comprises the nucleotide sequence shown as SEQ !D NO. 3 or SEQ ID NO. 4 or a nucleotide sequence which has at least 40% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4; and/or
- a foodstuff for human consumption comprising said lipolytic enzyme obtainable by a method of the present invention.
- the present invention yet further provides a transformed or transfected Trichoderma re ⁇ s ⁇ i cell comprising:
- nucleotide sequence comprises the nucleotide sequence shown as SEQ !D NO: 3 or SEQ ID NO: 4 or a nucie ⁇ tide sequence which has at least 40% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4;
- nucleotide sequence comprises a nucleotide sequence which hybridizes to SEQ ID NO: 3 or SEQ ID NO: 4 or a nucleotide sequence which is at least 40% sequence identity to SEQ !D NO. 3 or SEQ ID NO: 4 or the complement of any thereof under stringent conditions.
- the present invention provides an expression vector comprising
- nucleotide sequence which nucleotide sequence:
- a) encodes a lipolytic enzyme protein having at least 40% sequence identity to SEQ ID NO. 1 or 2; and/or
- b) encodes a lipolytic enzyme and comprises the nucleotide sequence shown as SEQ ID NO: 3 or SEQ !D NO: 4 or a nucleotide sequence which is at least 40% sequence identity to SEQ ID NO, 3 or SEQ ID NO. 4; and/or
- nucleotide sequence comprises a nucleotide sequence which hybridizes to SEQ ID NO: 3 or SEQ ID NO: 4 or a nucleotide sequence which is at least 40% sequence Identity to SEQ ID NO: 3 or SEQ ID NO: 4 or the complement of any thereof under stringent conditions;
- nucleotide sequence comprises the nucleotide sequence shown as SEQ ID NO: 3 or SEQ ID NO: 4 or a nucleotide sequence which is at least 40% sequence identity to SEQ ID NO; 3 or SEQ ID NO: 4, and/or
- nucleotide sequence comprises a nucleotide sequence which hybridizes to SEQ ID NO: 3 or SEQ ID NO. 4 or a nucleotide sequence which is at least 40% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4 or the complement of any thereof under stringent conditions;
- Trichoderma reesei is capable of producing the lipolytic enzymes in significantly high yields.
- lipolytic enzymes produced by the methodology of the present invention are surprisingly not overglycosylated and therefore have good enzyme activity
- the present invention provides a method of producing a lipolytic enzyme comprising the steps of:
- the level of expressed lipolytic enzyme is high enough so that one can use the broth medium into which the enzyme has been secreted (preferably after removal of the cell(s)) or in a concentrate form (preferably after removal of the CeII(S)).
- the method of the present invention includes the following additional step(s) of isolating and/or purifying and/or recovering the lipolytic enzyme
- the pH of the medium for culturing is about pH 4 to about 5,5, preferably about pH 4. In one embodiment, the pH of the medium for culturing is about pH 4
- the pH of the medium is raised at the end of the fermentation run when sufficient levels of the secreted, soluble enzyme are reached
- the Trichoderma reesei cell may comprise or be transfected or transformed with at least 2 heterologous nucleotide sequences encoding the lipolytic enzyme.
- the Trichoderma reesei cell may comprise or be transfected or transformed with at least 3, or at least 4, or at least 5 or at least 6 heterologous nucleotide sequences encoding the lipolytic enzyme.
- each heterologous nucleotide sequence is associated with and under the control of a promoter.
- each heterologous nucleotide sequence may have separate promoter associated with it and be under the control of that promoter
- heterologous nucleotide sequence is obtained or obtainable from a microorganism, particularly a fungi
- Trichoderma reesei cell has at least two genes encoding non-iipolytic enzymes suppressed.
- nucleotide sequence comprises the nucleotide sequence shown as SEQ ID NO. 3 or SEQ ID NO. 4 or a nucleotide sequence which has at least
- Trichoderma reesei cell has at least two genes encoding non-lipolytic enzymes suppressed
- the present invention yet further provides a lipolytic enzyme obtainable by the methods of the present invention
- nucleotide sequence comprises the nucleotide sequence shown as SEQ ID NO. 3 or SEQ ID NO: 4 or a nucleotide sequence which has at least 40% sequence identity to SEQ ID NO: 3 or SEQ ID NO. 4;
- At least two of the genes encoding a non-lipoiytic enzyme that is suppressed are celiuSase genes
- the heterologous nucleotide sequence may encode a lipolytic enzyme comprising an amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65% at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity to SEQ ID NO. 1 or SEQ ID No 2 or a sequence comprising one or several amino acid additions, deletions or substitutions compared to SEQ ID NO: 1 or SEQ ID No 2.
- the lipolytic enzyme produced by the present invention maybe glycosylated. In some embodiments, the lipolytic enzyme may be N-glycosylated at N32
- a further advantage of the present invention is that it provides an enhanced/increased expression and/or an improved yield of the lipolytic enzyme compared with conventional methods of expressing this lipolytic enzyme.
- an enhanced/increased expression and/or an improved yield of the lipolytic enzyme compared with production of the lipolytic in another host organism i e. a host organism other than T re ⁇ s ⁇ i.
- a further advantage of the present invention is that the lipolytic enzyme produced in accordance with the present invention is easy to produce and isolate and/or purify and/or concentrate
- the lipolytic enzyme according to the present invention is in a purified form.
- purified means that the given component is present at a high level
- the component is desirably the predominant component present in a composition Preferably, it is present at a level of at least about 60%, or at least about
- the amount is at least about 85% said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.
- nucleotide sequence in relation to the present invention includes genomic DNA 1 cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention .
- the nucleotide sequence when relating to and when encompassed by the perse scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is ⁇ nked to its naturally associated sequence(s) that is/are a!so in its/their natural environment
- the term “non-native nucleotide sequence” means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment
- the amino acid sequence encompassed by scope the present invention can be isolated and/or purified post expression of a nucleotide
- the nucleotide sequence encompassed by the scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA).
- the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et a/ , (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et a/ , (1980) Nuc Acids Res Symp Ser 225-232)
- amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques
- amino acid sequence when relating to and when encompassed by the per se scope of the present invention is not a native enzyme.
- native enzyme means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence
- the homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.
- % homology can be measured in terms of identity
- the alignment process itself is typically not based on an all-or-nothing pair comparison.
- a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
- An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs
- Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI AdvanceTM 1 1 package
- CLUSTAL may be used with the gap penalty and gap extension set as defined above
- the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides
- the present invention also encompasses the use of variants, homologues and derivatives of any amino acid sequence of a protein or of any nucleotide sequence encoding such a protein,
- the term “homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences
- the term “homology” can be equated with "identity”
- an homologous sequence is taken to include a nucleotide sequence which may be at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to a nucleotide sequence encoding an enzyme of the present invention (the subject sequence)
- the homofogues will comprise the same sequences that code for the active sites etc as the subject sequence
- homology can also be considered in terms of similarity (i e amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity
- Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs These commercially available computer programs can calculate % homology between two or more sequences
- % homology may be calculated over contiguous sequences, i e one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time This is called an "ungapped" alignment Typically, such ungapped alignments are performed only over a relatively short number of residues.
- BLAST and FASTA are available for offline and online searching (see Ausubel et a/, 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60)
- GCG Bestfit program A new tool called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2). 247-50, FEMS Microbiol Lett 1999 177(1).
- a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
- An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details), For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
- percentage homologies may be calculated using the multiple alignment feature in DNASISTM (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244)
- % homology preferably % sequence identity.
- the software typically does this as part of the sequence comparison and generates a numerical result
- sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
- Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained.
- negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophiiicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.
- the present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i e, like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc
- Non-homologous substitution may also occur i e from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine
- O pyriylalanine
- thienylalanine pyriylalanine
- naphthylalanine pyriylalanine
- phenylglycine pyriylalanine, thienylalanine, naphthylalanine and phenylglycine
- Replacements may also be made by unnatural amino acids include, alpha* and alpha- disubstituted * amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids such as trifluorotyrosine*, p-CI-phenyialani ⁇ e*, p-Br- phenylalanine*, p-i-phenylalanine * , L-ally!-glycine*, ⁇ -alanine * , L--amino butyric acid*,
- (Phe) such as 4-methyl-Phe * , pentamethyl-Phe*, L-Phe (4-amino)#, L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (I ⁇ .S ⁇ -tetrahydroisoquino ⁇ ne-S-carboxyl acid)*, L- diaminopropionic acid and L-Phe (4-benzyl)*
- the notation * has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #* indicates amphipathic characteristics
- Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethy!
- the peptoid form is used to refer to variant amino acid residues wherein the -carbon substituent group is on the residue's nitrogen atom rather than the -carbon Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et aA, PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol (1995) 13(4), 132-134.
- nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides
- a number of different types of modification to oligonucleotides are known in the art These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5 1 ends of the molecule
- the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences of the present invention
- the present invention also encompasses the use of nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.
- Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other homologues may be obtained and such homologues and fragments thereof in genera! will be capable of selectively hybridising to the sequences shown in the sequence listing herein.
- sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising ali or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency Similar considerations apply to obtaining species homologues and aiieiic variants of the polypeptide or nucleotide sequences of the invention
- Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention.
- conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues Sequence alignments can be performed using computer software known in the art For example the GCG Wisconsin PiIeUp program is widely used
- the primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences
- polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides
- Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e g. a PCR primer, a primer for an alternative amplification reaction, a probe e g labelled with a revealing label by conventional means using radioactive or nonradioactive labels, or the polynucleotides may be cloned into vectors
- primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.
- Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinant ⁇ , synthetically, or by any means available to those of skill in the art They may also be cloned by standard techniques
- primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art
- primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector
- the present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto
- hybridisation shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies
- the present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof
- variant also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein
- variant encompasses sequences that are complementary to sequences that are capable of hybridising under high stringent conditions (e g.
- the present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein),
- the present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein)
- polynucleotide sequences that are capable of hybridising to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.
- the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under stringent conditions (e.g. 5O 0 C and 0 2xSSC)
- the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g 65 0 C and 0 IxSSC).
- high stringent conditions e.g 65 0 C and 0 IxSSC.
- mutations or natural variants of a polynucleotide sequence can be recombined with either the wildtype or other mutations or natural variants to produce new variants
- Such new variants can also be screened for improved functionality of the encoded polypeptide
- the production of new preferred variants can be achieved by various methods well established in the art, for example the Error Threshold Mutagenesis (WO 92/18645), oligonucleotide mediated random mutagenesis (US 5,723, 323), DNA shuffling (US 5,605,793), exo-mediated gene assembly WO00/58517
- the application of these and similar random directed molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non- predictable but beneficial mutations or variants
- There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity include, but are not limited to one or more of the following.
- optimised expression and/or activity in a host cell or in vitro increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability, altered enzymatic activity/specificity in preferred environmental conditions, e g. temperature, pH, substrate
- sequence for use in the present invention is a recombinant sequence - i e a sequence that has been prepared using recombinant DNA techniques.
- sequence for use in the present invention is a synthetic sequence - i e a sequence that has been prepared by in vitro chemical or enzymatic synthesis It includes, but is not limited to, sequences made with optimal codon usage for host organisms T reesei
- the nucleotide sequence for use in the present invention may be incorporated into a recombinant replicable vector
- the vector may be used to replicate and express the nucleotide sequence, in protein form, in and/or from a compatible host cell
- Expression may be controlled using control sequences e g. regulatory sequences
- the protein produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellular ⁇ depending on the sequence and/or the vector used.
- the coding sequences may be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane
- expression vector means a construct capable of in vivo or in vitro expression
- the expression vector is incorporated into the genome of a suitable host organism
- the term "incorporated” preferably covers stable incorporation into the genome.
- the nucleotide sequence of the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host organism.
- the vectors for use in the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide of the present invention
- vector e g a plasmid, cosmid, or phage vector wi ⁇ often depend on the host cell into which it is to be introduced
- the vectors for use in the present invention may contain one or more selectable marker genes- such as a gene, which confers antibiotic resistance e g ampicillin, kanamycin, chloramphenicol or tetracyclin resistance Alternatively, the selection may be accomplished by co-transformation (as described in WO91/17243)
- Vectors may be used in vitro, for example for the production of RNA or used to transfect, transform, transduce or infect a host cell
- the invention provides a method of making nucleotide sequences of the present invention by introducing a nucleotide sequence of the present invention into a replicable vector, introducing the vector into a compatible host ceil, and growing the host DC! under conditions which bring about replication of the vector
- the vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question
- sequences are the origins of replication of piasrnids pUC19, pACYC177, pUBH G, pE194, pAMB1 and plJ702.
- the nucleotide sequence for use in the present invention is operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell.
- a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell.
- the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i e. the vector is an expression vector
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.
- regulatory sequences includes promoters and enhancers and other expression regulation signals.
- promoter is used in the normal sense of the art, e.g. an RNA polymerase binding site.
- Enhanced expression of the nucleotide sequence encoding the enzyme of the present invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.
- heterologous regulatory regions e.g. promoter, secretion leader and terminator regions.
- the nucleotide sequence according to the present invention is operably linked to at least a promoter
- Other promoters may even be used to direct expression of the polypeptide of the present invention
- Suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art
- a suitable promoter may be a cellobiohydrolase promoter
- a suitable promoter may be a cellobiohydrolase promoter obtainable (or obtained) from T reesei
- the promoter can additionally include features to ensure or to increase expression in a suitable host
- the features can be conserved regions such as transcription factor binding sites or deleted repressor binding sites
- construct which is synonymous with terms such as “conjugate”, “cassette” and “hybrid” - includes a nucleotide sequence for use according to the present invention directly or indirectly attached to a promoter
- an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention.
- a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron
- the term "fused" in relation to the present invention which includes direct or indirect attachment
- the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment
- the construct may even contain or express a marker, which allows for the selection of the genetic construct
- the construct of the present invention comprises at least the nucleotide sequence of the present invention operably linked to a promoter HOST CELLS
- host cell in relation to the present invention inciudes any T. reesei cell that comprises either the nucleotide sequence or an expression vector as described above and which is used in the recombinant production of a protein having the specific properties as defined herein
- a further embodiment of the present invention provides T reesei host cells transformed or transfected with a nucleotide sequence that expresses the protein of the present invention.
- T reesei host cell may provide for post-translationa! modifications ⁇ e g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.
- post-translationa! modifications ⁇ e g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation
- organism in relation to the present invention includes T. reesei that comprises the nucleotide sequence coding for the polypeptide according to the present invention and/or products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention when present in the organism,
- a suitable organism is T. reesei
- transgenic organism in relation to the present invention includes a T, reesei that comprises the nucleotide sequence coding for the polypeptide according to the present invention and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention within the organism.
- the nucleotide sequence is incorporated in the genome of the organism.
- transgenic organism does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is a!so in its natural environment
- the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the polypeptide according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention, or the products thereof
- transgenic organism may also comprise the nucleotide sequence coding for the polypeptide of the present invention under the control of a heterologous promoter
- Filamentous fungi cells may be transformed using various methods known in the art - such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known
- the host organism is T reesei and the like.
- the present invention encompasses the production of transgenic filamentous fungi according to the present invention prepared by use of these standard techniques.
- T. r ⁇ esei host cells transformed with the nucleotide sequence of the present invention may be cultured under conditions conducive to the production of the encoded polypeptide and which facilitate recovery of the polypeptide from the ce!l(s) and/or culture medium
- the transformed or transfected T, reesei cell(s) provided in accordance with the present invention is cultured under selective conditions to allow for selection of the cell(s) transformed or transfected with the lipolytic enzyme as defined herein
- the medium used to cultivate the celi(s) may be any conventional medium suitable for growing the host cell in questions and obtaining expression of the polypeptide
- the amino acid sequence for use according to the present invention may be produced as a fusion protein, for example to aid in extraction and purification.
- fusion protein partners include glutathione-S-transferase (GST), BxHis, GAL4 (DNA binding and/or transcriptional activation domains) and (-galactosidase). It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences
- the NOI may be engineered in order to alter their activity for a number of reasons, including but not limited to, alterations which modify the processing and/or expression of the expression product thereof.
- the NOI may also be modified to optimise expression in a particular host cell.
- Other sequence changes may be desired in order to introduce restriction enzyme recognition sites.
- a enzyme according to the present invention can further be used as an ingredient in food products such as American cheese sauce, anti-caking agent for grated & shredded cheese, chip dip, cream cheese, dry blended whip topping fat free sour cream, freeze/thaw dairy whipping cream, freeze/thaw stable whipped tipping, low fat & lite natural cheddar cheese, low fat Swiss style yoghurt, aerated frozen desserts, and novelty bars, hard pack ice cream, label friendly, improved economics & indulgence of hard pack ice cream, low fat ice cream: soft serve, barbecue sauce, cheese dip sauce, cottage cheese dressing, dry mix Alfredo sauce, mix cheese sauce, dry mix tomato sauce and others.
- the foodstuff is a beverage
- the foodstuff is a bakery product - such as bread, Danish pastry, biscuits or cookies
- Figure 2 shows a schematic of the method of the present invention
- Figure 5 shows results of a Lipase Activity Assay performed on supernatant from Trichoderma reesei transformants
- Figure 9 shows a southern blot showing transformed T. reesei strains that had been transformed with multiple copies of the "lipase 3" lipolytic enzyme gene, the lanes are labelled as follows:
- Figure 10 shows a protein profile by SDS-PAGE used to characterise the lipolytic enzyme ("lipase 3") expressed in Trichoderma reesei. Samples from cultures grown in different broths showed lipase 3 protein as double or triple bands.
- FIG 11a shows two different UFCs (ultra-filtration concentrates) showing precipitation of the lipolytic enzyme "lipase 3". Less concentrated protein in 1035 UFC shows heavy precipitation and more concentrated protein in 1036
- Figure 11 b shows an SDS-PAGE showing the presence of the lipolytic enzyme "lipase 3" protein in the precipitates of Figure 1 1 a: Lane 1 - Centrifuged filtered crude supernatant
- Figure 17 shows the nucleotide sequence encoding an Aspergillus tubingensis lipolytic enzyme (as shown in SEQ ID No. 1) including the signal sequence - the nucleotide sequence is a genomic DNA sequence (and has been designated as SEQ ID No- 3. The signal sequence is shown in bold and the intrans are shown in lower case.
- Figure 18 shows the nucleotide sequence encoding an Aspergillus tubingensis lipolytic enzyme (as shown in SEQ ID No 2) not including the signal sequence - the nucleotide sequence is a genomic DNA sequence (and has been designated as SEQ ID No 4. The introns are shown in lower case.
- FIG. 19 shows the sequence of the cellobiohydrolase 1 gene (cbh1) promoter designated SEQ ID No. 5.
- pDONRTM221 plasmid DNA obtained from Invitroqen (catalogue no 12536-017) was used as the donor vector pDONR221 ::lip 3 containing the Aspergillus tubingensis lipase 3 genomic DNA ( Figure 3) was recombined into the T reesei gateway destination vector pTrex3G (described in detail in WQ 05/001036), resulting in the final expression construct ATIipase3Trex ( Figure 4),
- the expression cassette contained the promoter and terminator regions of the T. reesei cellobiohydrolase 1 (cbh1) gene. It also contained the Aspergillus nidulans acetamidase, amdS gene as a selectable marker for transformation of T, reesei.
- the Aspergillus tubingensis ⁇ pase 3 genomic DNA encodes a lipase 3 lipolytic enzyme having the amino acid sequence shown in SEQ ID No 1.
- lipase 3 when used herein refers to a lipolytic enzyme comprising the amino acid sequence shown in SEQ ID No 2, such as the amino acid sequence shown in SEQ ID No 1 Seq ID No. 1 contains the signal seq and seq ID No 2 is the mature lipase protein without the signal sequence
- the strain used for transformation was Trichoderma reesei, a derivative of the non- GMM strain RL-P37 from which the genes encoding the two secreted cellobiohydrolases, CBHI and CBHII, and two of the secreted endoglucanases, EGI and EGII, have been deleted
- This vector is based on the £ coli vector pSL1180 (Pharmacia lnc , Piscataway, NJ, USA) which is a pUC118 phagemid based vector (Brosius, J. (1989) DNA 8:759) with an extended multiple cloning site containing 64 hexamer restriction enzyme recognition sequences. It was designed as a Gateway destination vector (Hartley, J L , Temple, G F and Bra ⁇ ch, M A (2000) Genome Research 10:1788-1795) to allow insertion using Gateway technology (Invitrogen) of any desired open reading frame between the promoter and terminator regions of the T reesei cbhl gene. It also contains the Aspergillus nidulans amdS gene for use as a selectable marker in transformation of T reesei.
- pTrex3g The details of pTrex3g are as follows The vector is 10 3 kb in size
- the expression construct, ATIipase3Trex, containing the A. tubingensis lipase 3 gene was transformed into a T. reesei strain using eiectroporation or biolistic transformation by particle bombardment using the PDS-1000 He ⁇ um system (BioRad Cat. No. 165- 02257) PCR products containing only fungal DNA or the entire expression plasmid were used for generating transformants by biolistic transformation and eiectroporation..
- the T reesei host strain to be transformed was grown to full sporulation on PDA plates for 5 days, Spores from 2 plates were harvested with 1.2M sorbitol and filtered through miracl ⁇ th to get rid of the agar. Spores were transferred to a 50 ml falcon tube and washed by repeated centrifugation 5-6 times with 50 ml water. The spores were resuspended in a small volume (iess than 2x pellet volume) using 1 2M sorbitol soiution.
- MM acetamide plates had the following composition. 0.6g/l acetamide; 1 ,68g/l CsCI; 20g/l glucose, 20g/l KH2PO4, 0.6g/l CaC!2 2H20, 1ml/! 1000x trace elements solution , 20g/i Noble agar, and pH5 5.
- 1000x trace elements solution contained 5 0g/l FeSO4 7H2O; 1.6g/l MnSO4; 1 .4g/l ZnSO4 7H2O and 1 0g/l CoC!2 6H2O.
- the spore suspension was allowed to dry on the surface of MM acetamide medium for 1 hour in the sterile hood. Transformation followed the manufacturer's instruction. ⁇ Omg of tungsten particles were placed in a microfuge tube. 1m! of ethanol was added and allowed to stand for 15 seconds The ethanol was removed and the particles were washed three times with ster ⁇ e dH 2 O before 25OuI of 50% (v/v) sterile glycerol was added.
- 25ul of tungsten particle suspension was placed onto a microfuge tube. While continuously vortexing, the following were added. 5ul (100-200 ng/ul) of piasmid DNA, 25ul of 2.5M CaCI2 and 10ul of 0.1M spermidine. The particles were centrifuged for 3 seconds, The supernatant was removed and the particles were washed with 200ui of 100% ethanol and centrifuged for 3 seconds. The supernatant was removed..
- transformants obtained by electroporation or by bioiistic transformation and displaying stable morphology were inoculated into 20OuI
- medium with g!ucose/sophorose in a 96-well microtiter plates defined medium with glucose/sophorose (per liter) consists of NH 4 2SO 4 5g, PIPPS buffer 33 g, Casamino Acids 9g, KH 2 PO 4 4.5 g, CaCS 2 (Anhydrous) 1g, MgSO 4 7H 2 O 1g, pH to 5 50 adjusted with 50% NaOH with milli-Q H2O bring to 966 5 mL After sterilization, the following were added.
- Lipase plate assay is based on the release of fatty acid from the substrate (tributyrin) in the presence of lipase. A pink colour is formed when fatty acid is released and forms a complex with Rhodamine B.
- the assay plate contained 2 Og Bacto Agar (dissolved by heating for 5 minutes in 100 ml 5OmM Sodium phosphate buffer pH 5 5. The solution was kept at 70 D C water bath and while stirring, 0 5m! 2% Rhodamine and 40ml tributyrin was added. The mixture was subjected to sonication for 2 minutes and 10-15 ml was poured into petri dishes.
- the protein profile of those transformants exhibiting high lipase activity was determined by SDS-PAGE using NuPAGE 4-12% polyacrylamide gels and MES as running buffer Samples of the supernatant were mixed with appropriate volume of 2x sample loading buffer with reducing agent The gels were stained with Simply blue
- Trichoderma reesei transformants were cultured in fermenters as described in WO 2004/035070 Four different transformants, generated by electroporation, were cultured Measurement of total protein and lipase activity in culture supernatants, after cell removal, indicated that in excess of 20 grams per liter lipase was present after 160 hours of fermentation Two strains, generated by bio ⁇ stic transformation, were also grown. These showed in excess of 20 grams per liter lipase in the culture supernatant after 160 hours of fermentation. The amount of lipase 3 produced by these transformants was far in excess of the amount of lipase 3 produced by other microbial host species (Figure 8)
- Trichoderma reesei transformants were cultured in fermentors. Four different transformants, generated by electroporation, were cultured. Measurement of total protein and lipase activity in culture supernatants, after cell removal, indicated that in excess of 20 grams per liter lipase was present after 160 hours of fermentation. Two strains, generated by biolistic transformation, were also grown. These showed in excess of 20 grams per liter lipase in the culture supernatant after 160 hours of fermentation. The amount of lipase 3 produced by these transformants was far in excess of the amount of lipase 3 produced by other microbial host species (Figure 8)
- Trichoderma reesei is capable of producing lipase 3 at very high levels.
- Down stream processing of the lipase after fermentation requires concentration of the culture broth 4x by ultrafiltration using a membrane with a 10,000 molecular weight cut-off.
- Lipase 3 is prone to precipitation as shown in Figure 11a, Heavy precipitation is observed in the more concentrated
- FIG 11a shows two different ultra-filtration concentrates (UFCs) showing precipitation of lipase 3 1035 UFC contains less concentrated protein and shows heavy precipitation. 1036 UFC contains more concentrated protein and shows very heavy precipitation.
- Figure 11 b shows an SDS-PAGE showing the presence of lipase 3 protein in the precipitates shown in Figure 11 a.
- Stock buffer consists of 1.0 M Na-Phosphate buffer, pH 8 0 Na 2 HPO 4 2H 2 O (177.99 g) added to 900 ml of Dl water.
- pH 4.44 was added 50, 100, 200, 400, and 500 ⁇ l of buffer stock solution to a final concentration of 5, 10, 20, 40, and 50 mM Na-Phosphate respectively All the vials were mixed and left at room temperature for a few minutes.
- Lipase 3 expressed by T reesi was purified from the culture supernatant using a combination of ion exchange and hydrophobic interaction chromatography Deglycosylation was carried out using endoglycosidase H in reaction buffer consisting of 50 mM Sodium Citrate, pH 5 5 Endogiycosidase H (2 0 mg/mL), was added to lipase 3 at a protein ratio from 1/1000 to 1/100 (w/w) The deglycosylation reaction was performed at 37°C for 3 hours The reacted protein sample was put on a ZipTip ® (Micro CU reversed-phase column) (Mil ⁇ pore, Bedford, MA) for sample cleanup prior to the MALDI-TOF/MS analysis The cleanup process was performed to desalt the samples At least five cycles of wash solution consisting of 5% methanol in 0.1% TFA/water wash was used Afterwards the samples were eiuted for mass spectrometry
- the desalted protein sample was prepared for MALD!-TOF/MS analysis by co- crystalizing an equal volume (1 ⁇ l_) of sample with Sinapinic acid matrix (saturated in 50% acetonitrile, 0 1 % formic acid) using the dried droplet method.
- Protein mass spectra were obtained using a Voyager DE-STR MALDl-TOF mass spectrometer (Applied Biosystems, Foster City, CA, USA)
- the MS instrument settings were as follows for the 20000-80000 m/z range: linear mode of operation, delayed extraction mode, positive polarity, 25 kV acceleration voltage, 93% grid voltage, and 750 nsec extraction delay time 300-laser shots/spectrum and BSA was used as external calibrant
- Lipase 3 has 2 potential N-glycosylation sites at N32 and N242 Peptide mapping was carried out for both lipase 3 (untreated) and Endo-H treated
- MS and MS/MS data were acquired using the SurveyorTM LC system coupled to the LCQ Advantage or LCQ Deca XP (ThermoFinnigan, San Jose, CA), The HPLC gradient was programmed from 0% to 70% B over 50 minutes.
- Solvent A 0 1% TFA in water and Solvent B. 0 08% TFA in acetonitrile Data Processing was performed using TurboSEQUEST and Xcaiibur (ThermoFinnigan, San Jose, CA).
- the purified lipase 3 was subjected to deglycosylation by treatment with endoglycosidase H.
- the untreated and the deglycosylated samples were characterised by measurement of specific activities using both short chain (C4) and long chain (C 18) substrates
- Table 2 shows the results of the deglycosylation experiments.
- the sample was Purified Trichoderrna lipase 3 and the deglycosylation enzyme was Endo-H.
- Figure 9 shows a southern blot showing transformed T, reesei strains that had been transformed with multiple copies of the "lipase 3" lipolytic enzyme gene, the lanes are labelled as follows.
- Lipase activity measured at the end of fermentation was 30,000 U/mL using DGGR assay.
- the broth was filtered and concentrated to UFC at high concentration the lipase appeared to precipitate. It was easily brought back into solution by diluting in buffer or salt EXAMPLE 9 Expression studies
- Table 3 provides the results of a series of expression studies.
- the present inventors have surprising found that the lipolytic enzyme "Lipase 3" produced in Trichoderma reesei is less glycosyiated (in particular less N-linked glycosylation) compared with the same enzyme produced in other organisms..
- the expression host cells suitable for use in the present invention may be a strain of T. reesei in which the genes encoding cellobiohydrolase I (CBHI, Cel7a), cellobiohydrolase II (CBHII 1 Cel6a), endoglucanase I (EGl, Cel7b), and endoglucanase H (EGII, CeISa) have been inactivated by deletion or disruption using molecular genetic techniques
- This strain (a quad delete strain) is useful as a host for over-expression of genes encoding other T, reesei secreted proteins.
- host cells suitable for use in the present invention may be derived from a Trichod ⁇ rma reesei cell of the strain RL-P37 using the methods described in WO 2005/001036 and US28026376 At
- T.reesei strain suitable for use in the present invention may be derived from the publicly available strain of T.reesei RL-P37
- T reesei strain RL-P37 may be modified to form T reesei strain 1 A52 as described in WO 05/001036
- T.reesei strain 1A52 may be modified as described in US 20080026376 to form a T reesei cell usable in the present invention.
- RL-P37 may be modified to form T reesei strain 1A52 as described below.
- the T. reesei host strain used may be derived from the publicly available strain RL- P37 which has previously been used to manufacture commercial cellulase preparations by Genencor International, lnc The derivation and characterisation of this strain has been published previously (Sheir-Neiss, G. and Montenecourt, B S. (1
- the pyr4 gene encodes orotidine-5'-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine
- the toxic inhibitor 5-fiuoroorotic acid (FOA) is incorporated into uridine by wild-type ceils and thus poisons the cells.
- FOA 5-fiuoroorotic acid
- cells defective in the pyr4 gene are resistant to this inhibitor but require uridine for growth It is, therefore, possible to select for pyr4 mutant strains using FOA. In practice, spores of T.
- the cbhl gene encoding the CBHI protein, was cloned from the genomic DNA of strain RL-P37 by hybridization with an oligonucleotide probe designed on the basis of the published sequence for this gene (Shoemaker, S , Schweickart, V , Ladner, M., Gelfand, D., Kwok, S,, Myamb ⁇ , K.
- flanking DNA Approximately 1 kb of flanking DNA remained from either end of the original Pstl fragment.
- the 7. reeseipyr4 gene was cloned as a 6 5 kb Hindill fragment of genomic DNA in pUCI8 to form pTpyr2 (Smith, J. L , Bayltss, FT and Ward, M (1991) Curr, Genet 19:27-33), The plasmid pUC4K..cbh1 ⁇ H/H was cut with Hindlil and the ends were dephosphorylated with calf intestinal alkaline phosphatase This DNA was ligated with the 6 5 kb Hindlll fragment containing the pyr4 gene to give p ⁇ CBHlpyr4
- Protoplasts isolated from mycelium of strain GC69 were transformed with EcoRI digested plasmid p ⁇ CBHIpyr4 using methods outlined by Smith et a/ , 1991. Stable transform ants were obtained and those from which the cbh 1 gene had been deleted were identified as described betow
- the cbh2 gene of T. reesei encoding the CBHIl protein, has been cloned as a 4.1 kb EcoRI fragment of genomic DNA (Chen et a/ , 1987, Biotechnology 5:274-278) This.4.1 kb fragment was inserted between the EcoRI sites of pUC4XL
- the latter plasrnid is a pUC derivative (constructed by R. Wl. Berka, Genencor Internationa! Inc.) which contains a multiple cloning site with a symetrical pattern of restriction endonuclease sites arranged in the order shown here.
- the plasmid, pP ⁇ CBHIl was constructed in which a 17 kb central region of this cbh2 clone, between a Hindll!
- the T reesei pyr4 gene was excised from pTpyr2 on a 1 6 kb Nhel-Sphl fragment and inserted between the Sphl and Xbai sites of pUC219 (derived from pUC119 by expanding the multiple cloning site to include restriction sites for BgIi!, CIaI and Xhol, Wilson et a!., 1989, Gene 77:69 78) to create p219M (Smith et al , 1991 , Curr, Genet 19.27-33)
- the pyr4 gene could then be removed as a Hindill-CIa!
- Protoplasts of strain P37P ⁇ CBHIPyr " 26 were generated and transformed with EcoRI digested pP ⁇ CBHIl according to the methods outlined in 3 above. Stable transformants were cultured in shake flasks and the protein in the culture supernatants was examined by isoelectric focussing One transformant (designated P37P ⁇ CBH67) was identified which did not produce any CBHI! (nor CBHi) protein,
- DNA was extracted from strain P37P ⁇ CBH67, digested with EcoRi and Asp718, and subjected to agarose gel electrophoresis The DNA from this gel was blotted to a membrane filter and hybridized with 32 P labelled pP ⁇ CBHIl The 4 1 kb EcoRI fragment containing the wildtype cbh2 gene was observed in the DNA from an untransformed control strain In contrast, in strain P37P ⁇ CBH67 the single 4 1 kb band was eliminated and replaced by two bands of approximately 0.9 and 3 1 kb ⁇ This is the expected pattern if a single copy of the larger EcoRI fragment from pP ⁇ CBHIl had integrated precisely at the cbh2 locus and deleted the cbh2 gene
- the egl2 gene encoding EGIi (previously referred to as EGIII by some), has been cloned from T. reesei and the DNA sequence published (Saloheimo et a/ , 1988, Gene 63:11-21). We have obtained the gene from strain RL-P37 as an approximately 4 kb Psti-Xho! fragment of genomic DNA inserted between the Pst! and Xhol sites of pUC219.
- the T, reesei pyr4 gene present on a 2 7 kb SaN fragment of genomic DNA obtained from pTpyr2, was inserted into a Sail site within the EGH coding sequence to create plasmid pEG!l..P-1 This resulted in disruption of the EGH coding sequence but without deletion of any sequences.
- the plasmid, pEGII..P-1 can be digested with Hindlll and BamHI to yield a linear fragment of DNA derived exclusively from T, reesei except for 5 bp on one end and 16 bp on the other end both of which are derived from the multiple cloning site of pUC219
- Strain P37P ⁇ CBH67Pyr ⁇ 1 was transformed with pEG!l:.P-1 which had been previously digested with Hindlli and BamHI and stable transformants were selected Total DNA was isolated from transformants and Southern analysis used to identify strains in which the fragment of plasmid DNA containing the pyr4 and eg/2 genes had integrated at the eg!2 locus and consequently disrupted the EGII coding sequence.. Southern analysis was performed using as a probe an approximately 4 kb Pstl fragment of 7. reesei DNA containing the eg!2 gene.
- the egl1 gene of T. reesei has been cloned and the DNA sequence of the gene has been published (Penttila et a/ , 1986, Gene 45;253-263; van Arsdel! et a/., 1987, Bsoltechnology 5:60-64), We have obtained this gene from T. reesei strain RL-P37 as a 4.2 kb Hindlll fragment of genomic DNA inserted at the Hindll!
- pUCIOO a derivative of pUC18 with an oligonucleotide inserted into the multiple cloning site adding restriction sites for BgIII, CIaI and Xhol
- pUCEGL An approximately 1 kb EcoRV fragment extending from a position close to the middle of the EGI coding sequence to a position beyond the 3' end of the coding sequence was removed and replaced by a 3.5 kb Seal fragment of 7 " . reesei DNA containing the pyr4 gene obtained from pTpyr2
- the resulting plasmid was called pP ⁇ EGI
- the plasmid, pP ⁇ EGI could be digested with Hindll! to release a DNA fragment comprising only T reesei genomic DNA having a segment of the egl1 gene at either end and the pyr4 gene, replacing part of the EGI coding sequence, in the centre
- pP ⁇ EGi Two forms of pP ⁇ EGi were constructed which differed only in the orientation of the pyr4 gene with respect to the egl1 flanking regions.
- Strain B31 P6 was transformed with a mixture of both forms of the plasmid after they had been digested with Hindll!. Total DNA was extracted from stable transformants, digested with Hindlll and subjected to Southern analysis.
- the probe used was radio labelled pUCEGL Hybridisation was observed to a 4.2 kb fragment of DNA from strain B31 P6 representing the undeleted ⁇ gl1 gene A transformant (strain 1A52) was identified in which this 4 2 kb was no longer present but had been replaced by a fragment of approximately 6 8 kb This is the pattern expected if the larger Hindlli fragment from pP ⁇ EG! had integrated precisely as predicted at the egl1 locus leading to deletion of part of the EGI coding sequence and insertion of pyr4 at this position Using a pUC plasmid as a probe for Southern analysis it was confirmed that the pUC DNA fragment of pP ⁇ EGI had not been incorporated in strain 1 A52
- Treesei strain 1A52 may be modified to form a Treesei cell usable in the present invention
- Determination of lipase activity by LIPU is carried out by enzyrnation of an emulsion of tributyrySglycerol Enzymatic hydrolysis of lipids liberates free fatty acids By continuous titration of the liberated free fatty acid, the lipase activity is determined from the consumption of base 1 LIPU (lipase unit) (also called 1 unit herein) is defined as the amount of enzyme, which releases 1 ⁇ mol free fatty acid per minute at the given assay conditions
- Enzyme samples were dissolved in demineralised water
- the titrant was 0 05 M NaOH
- the substrate was a homogenised emuision of 5% (v/v) tributyrinegiycerol
- reaction pH 5 5 and reaction temperature was 3O 0 C 2,00 mL sample was added to 25 0 mL substrate acclimatised to the reaction temperature
- Activity was calculated from the slope of a linear titration curve with consumption of titrant plotted against reaction time
- DGGR assay for Triacylglycerol hydrolysing activity This assay was used to measure Thermomyces lanuginos ⁇ s lipase expressed in Trichoderma,
- Buffer used is 0 5 M HEPES pH 8 + 60gpg 3:1 Ca:Mg Water hardness (see CAM300) and 4% Gum Arabic Lipase enzyme stock (1 mg/L) is used as standard.
- a 5OmL assay buffer is prepared by adding 5mL HEPES + Hardness and 25mL 4% Gum Arabic to 1OmL water.
- the assay buffer is incubated to desired assay temperature (typically 25 deg C).
- desired assay temperature typically 25 deg C.
- 1 OuL of enzyme samples are added into 96- weli plate at assay temperature 1-10ppm of active enzyme in sample recommended. For best results match unknown concentration to +/- two-fo!d activity of standard.
- the background rate (no enzyme, i e assay buffer) is determined
- 1 LIPU is defined as the quantity of enzyme which can liberate 1 mol butyric acid per minute under assay conditions.
- phospholipase A1 activity (E.C 3 1 1 32)
- phospholipase A2 activity (E C, 3, 1.1 4)
- phospholipase B activity (E.C 3 1.1 5)
- Amount of free fatty acid liberated during enzymation was measured using the NEFA C kit (999- 75406, WAKO, Germany) 56 ⁇ L NEFA A was added and the mixture was incubated for 300 s Afterwards 1 13 ⁇ L NEFA B was added and the mixture was incubated for 300s Afterwards 113 ⁇ l NEFAB was added and the mixture was incubated for 300s. OD 520 nm was then measured Enzyme activity LATU ( ⁇ mol FFA/minmL) was calculated based on a standard enzyme preparation Assay for glycolipase (galactolipase) activity.
- DGDG 5 Purified from wheat lipids
- Triton X-100 #T9284, Sigma
- 5 mM CaCI 2 dissolved in 50 mM HEPES buffer pH 7 0
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1006628A BRPI1006628B8 (en) | 2009-04-24 | 2010-04-23 | method to produce a lipolytic enzyme |
US13/265,712 US8940519B2 (en) | 2009-04-24 | 2010-04-23 | Method of producing a lipolytic enzyme |
DK10723329.8T DK2421963T4 (en) | 2009-04-24 | 2010-04-23 | PROCEDURE FOR THE PRODUCTION OF A LIPOLYTIC ENZYME |
CA2759405A CA2759405C (en) | 2009-04-24 | 2010-04-23 | Method |
CN201080018179.3A CN102439143B (en) | 2009-04-24 | 2010-04-23 | For the production of the method for lipolytic enzyme |
EP10723329.8A EP2421963B2 (en) | 2009-04-24 | 2010-04-23 | Method of producing a lipolytic enzyme |
ES10723329T ES2616057T5 (en) | 2009-04-24 | 2010-04-23 | Production method of a lipolytic enzyme |
AU2010240473A AU2010240473B2 (en) | 2009-04-24 | 2010-04-23 | Method of producing a lipolytic enzyme |
NZ595833A NZ595833A (en) | 2009-04-24 | 2010-04-23 | Method of producing a lipolytic enzyme |
US14/536,016 US9382523B2 (en) | 2009-04-24 | 2014-11-07 | Method of producing a lipolytic enzyme |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17227209P | 2009-04-24 | 2009-04-24 | |
US61/172,272 | 2009-04-24 | ||
GBGB0908770.1A GB0908770D0 (en) | 2009-04-24 | 2009-05-20 | Method |
GB0908770.1 | 2009-05-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/265,712 A-371-Of-International US8940519B2 (en) | 2009-04-24 | 2010-04-23 | Method of producing a lipolytic enzyme |
US14/536,016 Continuation US9382523B2 (en) | 2009-04-24 | 2014-11-07 | Method of producing a lipolytic enzyme |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010122531A2 true WO2010122531A2 (en) | 2010-10-28 |
WO2010122531A3 WO2010122531A3 (en) | 2010-12-29 |
Family
ID=40862772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/051802 WO2010122531A2 (en) | 2009-04-24 | 2010-04-23 | Method |
Country Status (11)
Country | Link |
---|---|
US (2) | US8940519B2 (en) |
EP (1) | EP2421963B2 (en) |
CN (1) | CN102439143B (en) |
AU (1) | AU2010240473B2 (en) |
BR (1) | BRPI1006628B8 (en) |
CA (1) | CA2759405C (en) |
DK (1) | DK2421963T4 (en) |
ES (1) | ES2616057T5 (en) |
GB (1) | GB0908770D0 (en) |
NZ (1) | NZ595833A (en) |
WO (1) | WO2010122531A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102604913A (en) * | 2012-04-05 | 2012-07-25 | 湖南尤特尔生化有限公司 | Preparation method and application of thermomyces lanuginosus lipase |
WO2013043860A1 (en) | 2011-09-22 | 2013-03-28 | Danisco Us Inc. | Endogenous dnase activity to reduce dna content |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0908770D0 (en) * | 2009-04-24 | 2009-07-01 | Danisco | Method |
US8759044B2 (en) | 2011-03-23 | 2014-06-24 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
US8765425B2 (en) | 2011-03-23 | 2014-07-01 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
CA2916609C (en) * | 2013-06-27 | 2022-05-03 | Sasol Technology (Proprietary) Limited | Production of biomass for use in the treatment of fischer-tropsch reaction water |
CN106434597B (en) * | 2016-11-08 | 2019-10-01 | 湖南尤特尔生化有限公司 | A kind of chaetomium thermophilum phosphatidase and its preparation method and application |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4797361A (en) | 1983-10-24 | 1989-01-10 | Lehigh University | Microorganism and process |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0229046B1 (en) | 1985-03-30 | 1994-05-04 | BALLIVET, Marc | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US5780292A (en) | 1987-04-29 | 1998-07-14 | Alko Group Ltd. | Production of phytate degrading enzymes in trichoderma |
DE69107455T3 (en) | 1990-05-09 | 2004-09-23 | Novozymes A/S | A CELLULASE PREPARATION CONTAINING AN ENDOGLUCANASE ENZYME. |
DE4112440C1 (en) | 1991-04-16 | 1992-10-22 | Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De | |
DK0673429T3 (en) | 1992-12-10 | 2002-10-07 | Dsm Nv | Preparation of heterologous proteins in filamentous fungi |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5741665A (en) | 1994-05-10 | 1998-04-21 | University Of Hawaii | Light-regulated promoters for production of heterologous proteins in filamentous fungi |
DE69835112T2 (en) * | 1997-04-09 | 2007-01-04 | Danisco A/S | Use of lipase to improve doughs and baked goods |
GB9821198D0 (en) * | 1998-09-30 | 1998-11-25 | Danisco | Enzyme |
WO2000043502A1 (en) | 1999-01-25 | 2000-07-27 | Novozymes A/S | Recovery of a protein at high ph |
JP2004500019A (en) | 1999-03-26 | 2004-01-08 | ディベルサ コーポレーション | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US7511005B2 (en) * | 2003-05-12 | 2009-03-31 | Danisco Us Inc., Genencor Division | Lipolytic enzyme elip |
EP1625208A4 (en) | 2003-05-12 | 2006-10-18 | Genencor Int | Novel lipolytic enzyme lip2 |
ES2371362T3 (en) | 2003-05-29 | 2011-12-30 | Genencor International, Inc. | NEW GENES OF TRICHODERMA. |
CA2595056A1 (en) * | 2005-01-24 | 2006-07-27 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
US7740307B2 (en) | 2006-06-14 | 2010-06-22 | Guido Benvenuto | Motor vehicle component and methods for its manufacture |
US20080026376A1 (en) | 2006-07-11 | 2008-01-31 | Huaming Wang | KEX2 cleavage regions of recombinant fusion proteins |
CN103451164A (en) * | 2006-07-14 | 2013-12-18 | 诺维信股份有限公司 | Methods for producing secreted polypeptides having biological activity |
ATE533841T1 (en) | 2007-03-14 | 2011-12-15 | Danisco Us Inc | TRICHODERMA REESEI A-AMYLASE TO ENHANCE THE SUGARIFICATION OF CORN STARCH |
EP2152892B1 (en) | 2007-05-21 | 2013-05-01 | Danisco US, Inc., Genencor Division | Method for introducing nucleic acids into fungal cells |
WO2008150376A1 (en) * | 2007-05-21 | 2008-12-11 | Danisco Us, Inc., Genencor Division | Use of an aspartic protease (nsp24) signal sequence for heterologous protein expression |
FI120835B (en) | 2007-07-10 | 2010-03-31 | Valtion Teknillinen | New esters and their use |
GB0908770D0 (en) * | 2009-04-24 | 2009-07-01 | Danisco | Method |
-
2009
- 2009-05-20 GB GBGB0908770.1A patent/GB0908770D0/en not_active Ceased
-
2010
- 2010-04-23 NZ NZ595833A patent/NZ595833A/en not_active IP Right Cessation
- 2010-04-23 US US13/265,712 patent/US8940519B2/en active Active
- 2010-04-23 CN CN201080018179.3A patent/CN102439143B/en active Active
- 2010-04-23 DK DK10723329.8T patent/DK2421963T4/en active
- 2010-04-23 AU AU2010240473A patent/AU2010240473B2/en active Active
- 2010-04-23 WO PCT/IB2010/051802 patent/WO2010122531A2/en active Application Filing
- 2010-04-23 CA CA2759405A patent/CA2759405C/en active Active
- 2010-04-23 BR BRPI1006628A patent/BRPI1006628B8/en active IP Right Grant
- 2010-04-23 EP EP10723329.8A patent/EP2421963B2/en active Active
- 2010-04-23 ES ES10723329T patent/ES2616057T5/en active Active
-
2014
- 2014-11-07 US US14/536,016 patent/US9382523B2/en active Active
Non-Patent Citations (31)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL, 1990, pages 403 - 410 |
ALTSCHUL ET AL., J. MOL. BIOL., 1990, pages 403 - 410 |
ARCHER; PEBERDY, CRIT REV BIOTECHNOL, vol. 17, no. 4, 1997, pages 273 - 306 |
AUSUBEL, SHORT PROTOCOLS IN MOLECULAR BIOLOGY, 1999, pages 77 - 5860 |
BEUCAGE S.L. ET AL., TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1869 |
BRADNER ET AL., CURRENT GENETICS, vol. 44, 2003, pages 224 - 230 |
BROSIUS, J., DNA, vol. 8, 1989, pages 759 |
CARUTHERS MH, NUC ACIDS RES SYMP SER, 1980, pages 215 - 23 |
CHEN ET AL., BIOTECHNOLOGY, vol. 5, 1987, pages 274 - 278 |
DAVIS; DE SERRES, METHODS ENZYMOL, vol. 17A, 1971, pages 79 - 143 |
DEVEREUX ET AL., NUC. ACIDS RESEARCH, vol. 12, 1984, pages 387 |
FEMS MICROBIOL LETT, vol. 174, no. 2, 1999, pages 247 - 50 |
FEMS MICROBIOL LETT, vol. 177, no. 1, 1999, pages 187 - 8 |
HARTLEY, J.L.; TEMPLE, G.F.; BRASCH, M.A., GENOME RESEARCH, vol. 10, 2000, pages 1788 - 1795 |
HIGGINS DG; SHARP PM, GENE, vol. 73, no. 1, 1988, pages 237 - 244 |
HORN T, NUC ACIDS RES SYMP SER, 1980, pages 225 - 232 |
HORWELL DC, TRENDS BIOTECHNOL., vol. 13, no. 4, 1995, pages 132 - 134 |
MATTHES ET AL., EMBO J., vol. 3, 1984, pages 801 - 805 |
MORINAGA, BIOTECHNOLOGY, vol. 2, 1984, pages 646 - 649 |
NELSON; LONG, ANALYTICAL BIOCHEMISTRY, vol. 180, 1989, pages 147 - 151 |
PENTTILA ET AL., GENE, vol. 45, 1986, pages 253 - 263 |
PUNT, TRENDS BIOTECHNOL, vol. 20, no. 5, May 2002 (2002-05-01), pages 200 - 6 |
SAIKI R K ET AL., SCIENCE, vol. 239, 1988, pages 487 - 491 |
SALOHEIMO ET AL., GENE, vol. 63, 1988, pages 11 - 21 |
SHEIR-NEISS, G.; MONTENECOURT, B.S., APPL. MICROBIOL. BIOTECHNOL., vol. 20, 1984, pages 46 - 53 |
SHOEMAKER, S.; SCHWEICKART, V.; LADNER, M.; GELFAND, D.; KWOK, S.; MYAMBO, K.; INNIS, M., BIOTECHNOLOGY, vol. 1, 1983, pages 691 - 696 |
SIMON RJ ET AL., PNAS, vol. 89, no. 20, 1992, pages 9367 - 9371 |
SMITH ET AL., CURR. GENET., vol. 19, 1991, pages 27 - 33 |
SMITH, J.L.; BAYLISS, F.T.; WARD, M., CURR. GENET., vol. 19, 1991, pages 27 - 33 |
VAN ARSDELL ET AL., BIOLTECHNOLOGY, vol. 5, 1987, pages 60 - 64 |
WILSON ET AL., GENE, vol. 77, 1989, pages 69 78 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013043860A1 (en) | 2011-09-22 | 2013-03-28 | Danisco Us Inc. | Endogenous dnase activity to reduce dna content |
EP2758514B1 (en) | 2011-09-22 | 2017-02-22 | Danisco US Inc. | Endogenous dnase activity to reduce dna content |
CN102604913A (en) * | 2012-04-05 | 2012-07-25 | 湖南尤特尔生化有限公司 | Preparation method and application of thermomyces lanuginosus lipase |
Also Published As
Publication number | Publication date |
---|---|
US9382523B2 (en) | 2016-07-05 |
EP2421963A2 (en) | 2012-02-29 |
BRPI1006628A2 (en) | 2015-08-25 |
DK2421963T3 (en) | 2017-03-06 |
WO2010122531A3 (en) | 2010-12-29 |
US20120196002A1 (en) | 2012-08-02 |
CA2759405A1 (en) | 2010-10-28 |
DK2421963T4 (en) | 2023-03-27 |
CN102439143A (en) | 2012-05-02 |
ES2616057T3 (en) | 2017-06-09 |
EP2421963B1 (en) | 2016-11-30 |
GB0908770D0 (en) | 2009-07-01 |
BRPI1006628B8 (en) | 2019-05-14 |
US8940519B2 (en) | 2015-01-27 |
AU2010240473A1 (en) | 2011-11-10 |
CA2759405C (en) | 2020-07-21 |
NZ595833A (en) | 2013-10-25 |
AU2010240473B2 (en) | 2014-01-30 |
EP2421963B2 (en) | 2022-12-28 |
BRPI1006628B1 (en) | 2019-04-16 |
ES2616057T5 (en) | 2023-05-23 |
US20150064309A1 (en) | 2015-03-05 |
CN102439143B (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9382523B2 (en) | Method of producing a lipolytic enzyme | |
AU2005290934C1 (en) | Citrobacter freundii phytase and homologues | |
JP3281508B2 (en) | Thermostable phytase | |
AU2005297167B2 (en) | Enzymes | |
WO2006038062A1 (en) | Microbial phytase as supplement to food or fodder | |
CA2812617A1 (en) | Pepsin-resistant alpha-amylases for use in feed supplement for monogastric animals | |
AU2010264116B2 (en) | Protein | |
US8507241B2 (en) | Cloning, expression and use of acid lysophospholipases | |
US6358722B1 (en) | Heat tolerant phytases | |
CN107849595A (en) | Aminopeptidase for protein hydrolysate | |
EP1542538A2 (en) | Lipase inhibitors and uses thereof | |
EP2116136A1 (en) | Novel phytases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080018179.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10723329 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 595833 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2759405 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8209/DELNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010240473 Country of ref document: AU Date of ref document: 20100423 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010723329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010723329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265712 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1006628 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1006628 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111021 |